Endo International Gets a Hold Rating from Cantor Fitzgerald

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Hold rating on Endo International (NASDAQ: ENDP), with a price target of $7. The company’s shares opened today at $6, close to its 52-week low of $5.27.

Chen commented:

“Takeaways from the quarter: 1) 1Q18 branded Specialty Products revenues increased 7% YOY to $112MM; 2) 1Q18 Xiaflex franchise revenues increased 15% YOY to $57MM; 3) 1Q18 Sterile Injectables revenues increased 25% YOY to $216MM; 4) ENDP continues to execute on its multi-year turnaround plan and build its portfolio for the future by advancing its CCH cellulite treatment development program with the initiation of and recruitment for two pivotal Phase 3 trials; 5) ENDP recently announced that it expects to significantly enhance its Sterile Injectables pipeline through the acquisition of Somerset Therapeutics. 6) as of 3/31/18, ENDP had $980MM in unrestricted cash, debt of $8.3B, net debt of ~$7.3B, and a net debt to adjusted EBITDA ratio of 5.1x; 7) 1Q18 cash provided by operating activities was $49MM; and 8) downward pressure on generic drugs prices appear to be stabilizing.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -11.3% and a 37.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.

Currently, the analyst consensus on Endo International is Hold and the average price target is $8.08, representing a 34.7% upside.

In a report issued on April 26, Guggenheim also maintained a Hold rating on the stock.

Find more picks by Best Performing Analysts >>

The company has a one-year high of $14.15 and a one-year low of $5.27. Currently, Endo International has an average volume of 4.96M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals. The U.S.